HC Wainwright Reaffirms “Buy” Rating for MetaVia (NASDAQ:MTVA)

MetaVia (NASDAQ:MTVA)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $20.00 price objective on the stock.

A number of other research firms also recently commented on MTVA. Weiss Ratings restated a “sell (e+)” rating on shares of MetaVia in a report on Friday, April 24th. Wall Street Zen raised shares of MetaVia to a “sell” rating in a research report on Saturday, June 20th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $20.00.

MetaVia Price Performance

Shares of NASDAQ MTVA opened at $1.73 on Friday. MetaVia has a one year low of $0.97 and a one year high of $19.03. The business’s 50-day moving average price is $1.90 and its two-hundred day moving average price is $2.66. The company has a market capitalization of $8.93 million, a P/E ratio of -0.33 and a beta of 0.97.

MetaVia (NASDAQ:MTVA) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). On average, equities analysts anticipate that MetaVia will post -2.78 EPS for the current year.

Institutional Trading of MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC purchased a new position in shares of MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia as of its most recent filing with the SEC. 1.37% of the stock is currently owned by hedge funds and other institutional investors.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.